TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

Monzr M. Al Malki; Yi-Bin Chen; Tania Jain; Alla Keyzner; Melhem M Solh; U. Popat; Michele Donato; Luis Piñeiro; Hugo F. Fernández; Saar I. Gill; Anson Snow; Joseph P. Uberti; Timothy P. White; Yun Wang; Cuong Manh Nguyen; Chrystal U. Louis; Shrikanta Chattopadhyay; Michelle Matzko; J. J. Stone

doi:10.1016/j.jtct.2025.12.206

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 1 trial finds TSC-101 may improve relapse-free survival in patients with AML, ALL, and MDS undergoing allogeneic HCT, suggesting a new treatment pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Malki et al. (2026) studied this question.

synapsesocial.com/papers/69a76096c6e9836116a2d79c https://doi.org/10.1016/j.jtct.2025.12.206

View at Publisher

Ask AI

Bookmark

Share

TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading